Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Camillo Porta

Showing results (311-320 of 388) with videos related to

Pageof 39
Sort By:
Nature Communications|April 10, 2026
Cabozantinib and temozolomide in patients with advanced progressive neuroendocrine tumors: a phase 2 studyMauro Cives, Giuseppina Della Vittoria Scarpati, Ottavia Clemente, et al.
Cancer|October 12, 2018
Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database ConsortiumSteven M Yip, Connor Wells, Raphael Moreira, et al.
Journal for Immunotherapy of Cancer|April 5, 2019
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access programElena Verzoni, Giacomo Cartenì, Enrico Cortesi, et al.
ESMO Open|November 28, 2020
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trialLaurence Albiges, Nizar M Tannir, Mauricio Burotto, et al.
Cells|January 11, 2022
Decrease of Pro-Angiogenic Monocytes Predicts Clinical Response to Anti-Angiogenic Treatment in Patients with Metastatic Renal Cell CarcinomaStephane Oudard, Nadine Benhamouda, Bernard Escudier, et al.
The Lancet. Oncology|February 22, 2014
Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trialRobert J Motzer, Camillo Porta, Nicholas J Vogelzang, et al.
European Urology Oncology|January 20, 2026
Outcomes of Patients with Metastatic Non-clear Cell Renal Cell Carcinoma Receiving Contemporary or Traditional First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database ConsortiumKosuke Takemura, Jeffrey Graham, David Maj, et al.
Tumori|July 3, 2019
Management of kidney cancer patients: 2018 guidelines of the Italian Medical Oncology Association (AIOM)Maria Giuseppa Vitale, Sergio Bracarda, Laura Cosmai, et al.
JAMA Network Open|January 21, 2021
Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With SurvivalShaan Dudani, Guillermo de Velasco, J Connor Wells, et al.
Frontiers in Oncology|March 18, 2024
Corrigendum: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib armsViktor Grünwald, Thomas Powles, Masatoshi Eto, et al.
Pageof 39

Showing results (311-320 of 388) with videos related to

Sort By:
Pageof 39
Nature Communications|April 10, 2026
Cabozantinib and temozolomide in patients with advanced progressive neuroendocrine tumors: a phase 2 studyMauro Cives, Giuseppina Della Vittoria Scarpati, Ottavia Clemente, et al.
Cancer|October 12, 2018
Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database ConsortiumSteven M Yip, Connor Wells, Raphael Moreira, et al.
Journal for Immunotherapy of Cancer|April 5, 2019
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access programElena Verzoni, Giacomo Cartenì, Enrico Cortesi, et al.
ESMO Open|November 28, 2020
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trialLaurence Albiges, Nizar M Tannir, Mauricio Burotto, et al.
Cells|January 11, 2022
Decrease of Pro-Angiogenic Monocytes Predicts Clinical Response to Anti-Angiogenic Treatment in Patients with Metastatic Renal Cell CarcinomaStephane Oudard, Nadine Benhamouda, Bernard Escudier, et al.
The Lancet. Oncology|February 22, 2014
Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trialRobert J Motzer, Camillo Porta, Nicholas J Vogelzang, et al.
European Urology Oncology|January 20, 2026
Outcomes of Patients with Metastatic Non-clear Cell Renal Cell Carcinoma Receiving Contemporary or Traditional First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database ConsortiumKosuke Takemura, Jeffrey Graham, David Maj, et al.
Tumori|July 3, 2019
Management of kidney cancer patients: 2018 guidelines of the Italian Medical Oncology Association (AIOM)Maria Giuseppa Vitale, Sergio Bracarda, Laura Cosmai, et al.
JAMA Network Open|January 21, 2021
Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With SurvivalShaan Dudani, Guillermo de Velasco, J Connor Wells, et al.
Frontiers in Oncology|March 18, 2024
Corrigendum: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib armsViktor Grünwald, Thomas Powles, Masatoshi Eto, et al.
Pageof 39